Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | CHEMO HEALTHCARE PRIVATE LIMITED | 7 | ₹3,900 |
| 2 | Schedule 2 | MAMMOTH LIFESCIENCES LLP | 10 | ₹87,000 |
| 3 | Schedule 3 | OM SHANTI MEDICOS | 8 | ₹17,220 |
| 4 | Schedule 4 | PHARMA (INDIA) | 8 | ₹15,180 |
| 5 | Schedule 5 | SUNIL PHARMACY | 7 | ₹9,360 |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
13 Jul 2026, 11:00 amClosed
ARIPIPRAZOLE 10 MG TAB
GLICLAZIDE 30 MG MR TAB
CHLORTHALIDONE 6.25 MG TAB
BRIVARACETAM 50 MG TAB
PIOGLITAZONE 15 MG TAB
RISPERIDONE 4 MG TAB
AMANTADINE 100 MG CAP
9527538
GEM/2026/B/7717272
Two Packet Bid
ARIPIPRAZOLE 10 MG TAB,GLICLAZIDE 30 MG MR TAB,CHLORTHALIDONE 6.25 MG TAB,BRIVARACETAM 50 MG TAB,PI
Mumbai, Maharashtra
Item wise evaluation
BOQ
7 documents required · 7 mandatory
2 yrs
₹1 L
₹1 L
20%
Exempted
Yes
13 Jul 2026
2 Jul 2026
13 Jul 2026
| Item No | Item Title | Qty | Unit | Consignee | Delivery (days) |
|---|---|---|---|---|---|
| 1 | ARIPIPRAZOLE 10 MG TAB | 1,000 | NO | Mumbai | 30 |
| 2 | GLICLAZIDE 30 MG MR TAB | 1,50,000 | NO | Mumbai | 30 |
| 3 | CHLORTHALIDONE 6.25 MG TAB | 42,000 | NO | Mumbai | 30 |
| 4 | BRIVARACETAM 50 MG TAB | 6,600 | NO | Mumbai | 30 |
| 5 | PIOGLITAZONE 15 MG TAB | 24,000 | NO | Mumbai | 30 |
| 6 | RISPERIDONE 4 MG TAB | 1,500 | NO | Mumbai | 30 |
| 7 | AMANTADINE 100 MG CAP | 9,600 | NO | Mumbai | 30 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_9527538.pdf
GEM_BID • 0.14 MB
bbqr_echs_2026-06-27-12-35-58_f0b243a6eb67b9d7a6bf1869253c2e7c.pdf
BOQ • 0.29 MB
aripiprazole_2026-06-27-12-35-58_f905d534e19f4e2034454fd47b27b95d.csv
BOQ • 0.00 MB
gtc.pdf
GEM_OTHER • 0.71 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .